Synlogic, INC Form 4 insider transactions

Synlogic and Caldera Therapeutics announce a merger agreement, creating a combined entity focused on advancing CLD-423 for inflammatory bowel disease, supported by a $278 million private placement.

SYNLOGIC's Principal Executive and Financial Officer, Mary Beth Dooley, sold 157 shares of common stock to cover tax liabilities related to a restricted stock award.

Director Richard P. Shea acquired 15,000 shares of Synlogic, Inc. restricted stock on April 26, 2025, which will fully vest on December 15, 2025, pending continued service as a Non-Employee Director.

Director James P. Flynn acquired 15,000 shares of Synlogic, Inc. restricted stock on April 26, 2025, as part of the Non-Employee Director Compensation Program.

Mary Beth Dooley, Principal Executive Officer and Principal Financial Officer of Synlogic, Inc., sold 144 shares of common stock on April 2, 2025, to cover tax liabilities associated with vesting restricted stock awards.

Mary Beth Dooley, Principal Executive Officer and Principal Financial Officer of Synlogic, Inc., sold 2,107 shares of common stock to cover tax liabilities related to a restricted stock award.

Mary Beth Dooley, Head of Finance at Synlogic, Inc., sold 79 shares of common stock on October 29, 2024, to cover tax liabilities related to a restricted stock award.

Mary Beth Dooley, Head of Finance at Synlogic, sold 188 shares of common stock on April 2, 2024, to cover tax liabilities related to vesting restricted stock awards.

Synlogic's Chief Operating Officer, Antoine Awad, sold 372 shares of common stock on April 2, 2024, to cover tax liabilities related to vesting restricted stock awards.

Director James P. Flynn reports the acquisition of stock options in Synlogic, Inc.